AI Summary

A joint research team led by the LKS Faculty of Medicine at the University of Hong Kong, together with collaborators from the Chinese University of Hong Kong, New York University and Newcastle University, has identified that a combination of policy adjustments and service measures could improve the value and affordability of esketamine nasal spray, a novel rapid‑acting treatment for treatment‑resistant depression. The findings suggest that coordinated changes in reimbursement, pricing and delivery models may make the therapy more accessible to patients who need it.

AI summaries can be wrong sometimes—always verify important details using the source article.